TY - JOUR T1 - Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P288 AU - Anthony D'Urzo AU - Donald A. Mahler AU - Petter Olsson AU - Hungta Chen AU - Robert Fogel AU - Donald Banerji Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P288.abstract N2 - IntroductionThe BLAZE study reported the superiority of an approved dual bronchodilator, QVA149 (GOLD group B-D), in terms of improvement in self-administered computerised version of transitional dyspnoea index (SAC-TDI) total score and lung function vs placebo (PBO) and tiotropium (TIO) in patients (pts) with COPD.1 Here, we present improvements in dyspnoea, lung function, and rescue medication use in the subgroup of pts on prior LAMA therapy.MethodsIn this blinded, double-dummy, 3-period crossover study, pts (with mMRC≥2) with moderate-to-severe COPD were randomised to once-daily QVA149 110/50µg, PBO or TIO 18µg.ResultsOf the 247 pts randomised, 115 were on prior LAMA therapy. Of these 115 pts, a higher proportion of pts on QVA149 reported ≥1unit improvement in the SAC-TDI total score (36.5%) vs PBO (16.4%; odds ratio [OR] 3.71; p<0.001) and TIO (20.2%; OR 2.51; p=0.007). At Day 1 and Wk 6, QVA149 provided significant improvements in mean FEV1 at all assessed time-points and FEV1 AUC0–4h vs both PBO and TIO (table). QVA149 significantly reduced (p<0.001) mean daily rescue medication use (puffs/day) by 1.55 vs PBO and by 0.68 vs TIO.View this table:Least squares mean treatment difference values of FEV1 and FEV1 AUC0-4h (mL)ConclusionIn the subgroup of pts on prior LAMA therapy, QVA149 significantly improved SAC-TDI total score and lung function while also reducing rescue medication usage vs PBO and TIO.Reference:1. Mahler et al. Eur Respir J 2013 Oct 31 (in press). ER -